News

Omitting NRTIs safe with optimized HIV regimen

Publish date: March 25, 2013

 

AT CROI 2013

The National Institute of Allergy and Infectious Diseases funded the study. The study drugs were supplied by Merck, Janssen, Pfizer, Hoffmann-La Roche, and Boehringer Ingelheim. Monogram Biosciences provided resistance and tropism testing. Dr. Tashima reported honoraria from Gilead Sciences.

Pages

Recommended Reading

Meta-analysis bolsters strength of tuberculosis assay
MDedge Internal Medicine
FDA panel picks strains for next flu season's vaccine
MDedge Internal Medicine
'Nightmare' CRE infections on the rise, CDC says
MDedge Internal Medicine
Interferon-free regimen cures 100% of hard-to-treat hepatitis C
MDedge Internal Medicine
FDA issues warning on azithromycin arrhythmia risk
MDedge Internal Medicine
Head, neck infections rising among children
MDedge Internal Medicine
Steroids may decrease length of hospital stay for pneumonia
MDedge Internal Medicine
Rabies death follows infected organ transplant
MDedge Internal Medicine
Eritoran fails to improve mortality in severe sepsis
MDedge Internal Medicine
Mold again found in compounded product
MDedge Internal Medicine